Target Audience and Goal Statement
This activity is intended for cardiologists, infectious disease clinicians, endocrinologists, diabetes specialists, PCPs,
nurses, pharmacists and all clinicians interested in statin therapy in special populations.
The goal of this activity is to outline the role of statin therapy as a strategy to reduce cardiovascular risk in persons
with HIV infection.
Upon completion of this activity, participants will have:
Increased knowledge regarding the:
- Burden of cardiovascular disease (CVD) in patients with HIV infection
- The role of statin therapy to prevent CVD in patients with HIV infection
Increased competence related to:
- The ability to tailor statin therapy in patients with HIV infection
Disclosures
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of
an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant
financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial
relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food
and Drug Administration, at first mention and where appropriate in the content.
Faculty

-
James A. Underberg, MD
Clinical Assistant Professor of Medicine, NYU School of Medicine; Director, Bellevue Hospital Lipid Clinic, NYU Center for
Prevention of Cardiovascular Disease, New York, New York
Disclosures
Disclosure: James A. Underberg, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amgen Inc.; Lilly; Merck & Co.,
Inc.; Recombine
Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Merck & Co., Inc.; Regeneron
Pharmaceuticals, Inc.; Sanofi
Received grants for clinical research from: Aegerion Pharmaceuticals; Pfizer Inc.
Dr Underberg does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by
the FDA for use in the United States.
Dr Underberg does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the
FDA for use in the United States.

-
Steven Grinspoon, MD
Professor of Medicine, Harvard Medical School; Director, Program in Nutritional Metabolism and Nutrition Obesity Research
Center, Massachusetts General Hospital, Boston, Massachusetts
Disclosures
Disclosure: Steven Grinspoon, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Navidea Biopharmaceuticals; Theratechnologies Inc.
Received grants for clinical research from: Gilead Sciences, Inc.; Kowa Company Ltd.; Navidea Biopharmaceuticals; Theratechnologies
Inc.
Dr Grinspoon does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by
the FDA for use in the United States.
Dr Grinspoon does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved
by the FDA for use in the United States.
Chair
-
Peter P. Toth, MD, PhD
Professor of Clinical Family and Community Medicine, University of Illinois; Director of Preventive Cardiology, CGH Medical
Center, Sterling, Illinois
Disclosures
Disclosure: Peter P. Toth, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amarin Corporation plc; Amgen Inc.; AstraZeneca; Kowa Company Ltd.; Merck & Co., Inc.;
Regeneron Pharmaceuticals, Inc.; Sanofi
Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Kowa Company Ltd.; Merck & Co.,
Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
Members
-
Judith A. Aberg, MD
Professor of Medicine; Chief, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York
Disclosures
Disclosure: Judith A. Aberg, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck & Co., Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; GlaxoSmithKline; Gilead Sciences, Inc.
-
Sergio Fazio, MD, PhD
Professor of Medicine; Director of Preventive Cardiology, Oregon Health & Science University, Portland, Oregon
Disclosures
Disclosure: Sergio Fazio, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Aegerion Pharmaceuticals, Inc.; Amarin Corporation plc; Amgen Inc.; Invitae Corporation;
Kowa Company Ltd.; Merck & Co., Inc.; Sanofi
Editor
CME Reviewer / Nurse Planner
Peer Reviewer
This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: Served
as an advisor consultant for: HeartWare; Medtronic; St Jude Medical; Thoratec.
Accreditation Statements
Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education
(ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare
team.
For Physicians
-
Medscape, LLC designates this enduring material for a maximum of 0.50
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant
to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity
provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this activity.
Contact This Provider
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated
at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.